Our
Science

Coeptis Therapeutics, Inc. has entered into an exclusive license agreement with the University of Pittsburgh for certain intellectual property rights to technologies developed within research laboratories at the University of Pittsburgh. Chimeric antigen receptors (CARs) are artificial T cell receptors that re-target T cells to specifically recognize and kill tumor cells. The licensing agreement involve a CAR T cell therapy platform called “SNAP CAR” designed to be a universal therapeutic in the treatment of various types of cancer. The SNAP-CAR T cell therapy is currently in preclinical development.

Through our subsidiary, Coeptis Pharmaceuticals, we have entered into co-development agreements with VyGen-Bio, led by its team of leading medical researchers at the Karolinska Institutet (KI) based in Stockholm, Sweden, to jointly develop novel natural killer cell-based therapeutics and related diagnostics with an initial focus on the urgent need to improve treatments for cancers that over-express the CD38 protein (CD38+).

Our
Scientific Collaboration

• Coeptis is collaborating with researchers from the University of Pittsburgh and contracted a prominent Clinical Research Organization (CRO) to begin developing the SNAP-CAR T cell therapy with the goal to pursue clinical trials. Coeptis has been assigned the worldwide development and commercialization rights to the licensed technology in the field of human treatment of cancer with antibody or antibody fragments using SNAP-CAR T cell technology.
• VyGen-Bio is a discovery-stage, cell-based immunotherapy company focused on the development of transformational technology platforms: GEAR-NK, modified natural killer cell-based therapeutics (NK cells), optimized to be co-administered with targeted antibodies; and, GEAR Diagnostic, a companion diagnostic being developed to select patient populations most likely to benefit from targeted antibody therapies.
• Headquartered in Tampa, Florida on the campus of the H. Lee Moffitt Cancer Center, VyGen-Bio is a majority-owned subsidiary of Vycellix, Inc. VyGen-Bio’s platforms were discovered by scientists at Karolinska Institutet (KI), Stockholm, Sweden that collaborate with VyGen-Bio. Additionally, VyGen-Bio is a member-partner in “NextGenNK”, an international Competence Center for the development of next-generation NK cell-based cancer immunotherapies based at KI and funded by Sweden’s innovations agency, Vinnova. KI is globally recognized for its Nobel Assembly, which awards the Nobel Prize in Physiology or Medicine.

NOVEL CELL
THERAPIES IN
CLINICAL TRIALS 

NK Cells and FDA Approved IND Applications  

The acquisition includes key assets developed by Deverra Therapeutics and gives Coeptis exclusive rights to two Investigational New Drug applications and two Phase-1 clinical trials evaluating DVX201, an unmodified natural killer cell therapy generated from pooled, cord blood derived CD34+ cells. In addition to the clinical assets being acquired, Coeptis is adding a scalable, allogeneic cellular immunotherapy platform that is designed to  generate off-the-shelf, cost-effective and on-demand immune effector cell therapies to a broad patient population. 

This transaction significantly expands the Coeptis pipeline with the addition of a patented and scalable allogeneic immune effector cell manufacturing platform that aligns with the existing Coeptis SNAP-CAR and GEAR technologies.  These assets are key in providing the potential for accelerated product development within the Coeptis portfolio and for improved patient outcomes in otherwise difficult to treat cancers.